CD38-directed Antibody Interactions [MoA] - N0000192335

Pharmacologic Code	N0000192335
Pharmacologic Name	CD38-directed Antibody Interactions
Pharmacologic Uses	CD38-directed cytolytic antibody
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

The table contains 5 products whose active ingredient are classified under the same pharmacologic class CD38-directed Antibody Interactions [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0024-0654	Sarclisa	Non-Proprietary Name: Isatuximab	Injection, Solution, Concentrate	Intravenous	Sanofi-aventis U.s. Llc	ACTIVE
	0024-0656	Sarclisa	Non-Proprietary Name: Isatuximab	Injection, Solution, Concentrate	Intravenous	Sanofi-aventis U.s. Llc	ACTIVE
	57894-502	Darzalex	Non-Proprietary Name: Daratumumab	Injection, Solution, Concentrate	Intravenous	Janssen Biotech, Inc.	ACTIVE
	57894-503	Darzalex Faspro	Non-Proprietary Name: Daratumumab And Hyaluronidase-fihj (human Recombinant)	Injection	Subcutaneous	Janssen Biotech, Inc.	ACTIVE
	57894-505	Darzalex Iv	Non-Proprietary Name: Daratumumab	Injection, Solution, Concentrate	Intravenous	Janssen Biotech, Inc.	ACTIVE